News & Events

Liquid Biopsy Pioneer SanoLiBio announces Nomination of its Advisory Board Munich

SanoLiBio GmbH, a leading player in liquid biopsy innovation, announced today the nomination of its advisory board: Members are Bruno Steis (Gray Fox Consulting GmbH), Dr. Peter Frost (PELOBiotech GmbH) and Dr. Bernhard Polzer (ITEM Fraunhofer). The long-standing partner at Siemens Venture Capital and former CEO of inge GmbH Bruno Steis acts as chairman. Board Member Dr. Peter Frost serves as expert in the Life Sciences sector by supervising the Sales&Marketing activitities. Dr. Bernhard Polzer contributes to the success of Sanolibio as a clinical networker and with his expert knowledge on cancer diagnostics based on his leading position at Fraunhofer ITEM.

The board supports the management to position SanoLiBio for further growth by bringing deep domain expertise in company building, sales and marketing and R&D to the table. It facilitates the current fundraising process as well.

“To enrich circulating rare cells, such as circulating tumor cells is one of the key factors in the growing market of liquid biopsy”, says board member Dr. Peter Frost, CEO of PELOBiotech, one of the leading cell culture companies, outlining the need for technological innovations. SanoLiBio uses a novel magnetic bead cell separation procedure that allows high-sensitive detection of rare cells in blood samples. Based on the power of their technology, SanoLibio is confident to advance early diagnosis and prevention.

The company is seeking funding in order to introduce its enrichment platform “Walderbach” to the market in H1 2020.

About SanoLiBio GmbH

SanoLiBio focuses on the ultra-high enrichment of rare cells, such as circulating tumor cells, taken from liquid biopsy. The overall liquid biopsy market will grow to USD 10,7bn by 2026, a CAGR of 24.2%. Thereof, the sub-segment of cancer will grow with a CAGR of 52,4%. (Source: BCC Research, Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets October 2017).

The Medtech-Startup was founded 2017 located in Munich at the Biotech-Hotspot in Europe. CEO is Dr. Stefan Schreier who leads the company together with Timo Peter (COO) and Ulrich Lang (CTO).

About “Walderbach”

The company will introduce its fully automated cell enrichment platform, named “Walderbach”, as a new benchmark in rare cell isolation from 2020 onwards internationally. The platform allows early stage cancer diagnostic in a fast, reliable and affordable way for the very first time. The enrichment platform is named “Walderbach” after the CEO’s home town.

About the board
Bruno Steis (Chairman)

• In total 35 years professional experience in leading management functions, both in large corporations and technology start-ups
• Senior Investment Partner (9 years) at Siemens Venture Capital with responsibility for numerous investments in technology firms, incl. membrane manufacturer inge AG
• 40 years cumulated experience as Chairman/Member of Supervisory and Advisory Boards

Dr. Peter Frost (Member)
• More than 20 years experience in Sales & Marketing of Life Science products for basic and clinical research. Introduced successfully innovative Biotech companies in the European as well as US market (e.g. SpheroTec, Sirion Biotech, InSphero)
• Was involved in the market entry of StemCell´s RoboSep, a automated cell separation system
• Developed PELOBIOTECH GmbH to one of the leading cell culture companies

Dr. Bernhard Polzer (Member)
• More than 15 years’ experience in R&D and publication record on single cell analysis, liquid biopsy and cancer metastasis
• Background in human medicine and translation of new technologies in clinical applications
• Group leader „Cellular and Molecular Diagnostics“ at Division „Personalized Tumor Therapy“ of Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg

For Press Contacts: Timo Peter, COO
M: +49 172 8889848

SanoLiBio will pitch at the 2019 Biotech Investors Day in Würzburg on April 8th, 2019. Do you want to meet? Don’t hesitate to contact us.
Learn more:

SanoLiBio will particpate in the 2018 Sino-Europe Innovation Week of Health Technology – “Innovation for Health” – event organized by International Co-Innovation Center for Advanced Medical Technology (iCCAMT). On this roadshow the team will present SanoLiBio’s rare cell enrichment platform to potential clients and investors in Shenzhen, Shanghai and Nanjing. Do you want to meet? Don’t hesitate to contact us.
Learn more:

SanoLiBio will particpate in the Elevator Pitch Competition (EPiC) 2018 event organized by Hong Kong Science and Technology Parks Corporation (HKSTP). The team will pitch among 100 international start-ups in the elevator of and at Sky100, the hundreth floor of the International Commerce Centre tower. Do you want to meet? Don’t hesitate to contact us.
Learn more:

SanoLiBio will particpate from Oct 15-20 in the US EIT Health GoGlobal programm organized by the Nürnberg Mecial Valley. The team will meet potential customers, partners and investors in New York and Boston. This will give SanoLiBio a major push towards our market entry USA and internationalization at all. Do you want to meet? Don’t hesitate to contact us.

Today, the SanoLiBio team achieved a major milestone. Our first cell enricher single device has been shipped to our clinical partner Premise Diagnostic, Thailand.
The device will be primarily used to generate medical data and validate our process. Management expects to ship first products to customers H1 2020.

SanoLiBio attends the Baker McKenzie Bio Tech Seminar “Investing in Biotech in Europe from Seed to Exit: Latest Trends”. Contact and meet us:

SanoLiBio has been selected to participate in the GoGlobal programm of the Medical Valley Nürnberg. The programms support innovative growth companies with advise on how to establish an international business, gives access to oversea customers and partners and organizes a roadshow to key regions. For SanoLiBio these are the US and Asia.

SanoLiBio attends the 3rd Munich Life Science Pitch Day at the IZB. Contact and meet us:

SanoLiBio participates in the Start-up Challenge at Deutsche Biotechnologietage 2017 in Hannover.
SanoLiBio has been selected to pitch at the Start-up Challenge event at Deutsche Biotechnologietage 2017, 5. to 6. April in Hannover. We are looking forward to meeting you.